E-mail
Contact Us
home Drug Peptide Semaglutide

Semaglutide

CAS No.: 910463-68-2
Semaglutide Chemical Structure

Molecular formula: C187H291N45O59

Molecular weight: 4113.5775

Patent period: Compound: 2026 Composition: 2029

Dositive specifications: 1.34mg/ml

Injection : 1.5ml, 3.0ml/support

Oral tablets: 3mg, 7 mg, 14 mg, once a day

Injection (weight loss, wegovy): 2.4mg/0.75ml

Products are for laboratory research use only. Not for human use. We do not sell to patients.
Biological Activity

Semaglutide causes thyroid C-cell tumors. It is unknown whether OZEMPIC causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of semaglutide-induced rodent thyroid Ccell tumors has not been determined.

There are currently three FDA-approved semaglutide products:

__ Ozempic

__ Rybelsus

__ Wegovy

Chemical Properties

ACTIONS

Agonist

CAS NO.

910463-68-2

FORMULA

C187H291N45O59

M.WT

4113.64

PURITY

>98%

SYNONYMS

Ozempic

Rybelsus

Wegvoy

STORAGE

The shelf life of the drug product is 36 months at 5℃, and the in-use shelf life is 56 days at 5℃ to 30℃ after initial use.

Online Inquiry
Product Online Inquiry
Other Drug Peptide More+